Sugi Predict

Sugi Predict / Compounds / SCHEMBL620331

SCHEMBL620331

SCHEMBL620331

O=[N+]([O-])c1ccc2ncc(Cl)nc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.49
▸ TXNRD1 Q16881 1/20 0.49
▸ TXNRD3 Q86VQ6 1/20 0.49
▸ TXNRD2 Q9NNW7 1/20 0.49
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 2/20 0.46
▸ NAMPT P43490 1/20 0.46
▸ XDH P47989 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ GUCY1B2 O75343 1/20 0.46
▸ GUCY1A2 P33402 1/20 0.46
▸ GUCY1A1 Q02108 1/20 0.46
▸ GUCY1B1 Q02153 1/20 0.46
▸ KMT2A Q03164 3/20 0.44
▸ OPRK1 P41145 1/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ MAPT P10636 2/20 0.43
▸ LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30891041 0.93 ALDH1A1 (0.49) ALDH1A1TXNRD1TXNRD3TXNRD2CYP1A2
SCHEMBL3567491 0.93 ALDH1A1 (0.49) ALDH1A1TXNRD1TXNRD3TXNRD2CYP1A2
SCHEMBL31439301 0.87 ALDH1A1 (0.54) ALDH1A1TXNRD1TXNRD3TXNRD2CYP1A2
SCHEMBL28008455 0.87 ALDH1A1 (0.54) ALDH1A1TXNRD1TXNRD3TXNRD2CYP1A2
SCHEMBL18743108 0.81 ALDH1A1 (0.50) ALDH1A1TXNRD1TXNRD3TXNRD2CYP1A2
SCHEMBL8892090 0.80 ALDH1A1 (0.50) ALDH1A1TXNRD1TXNRD3TXNRD2CYP1A2
SCHEMBL12814503 0.80 SMN1; SMN2 (0.50) ALDH1A1TXNRD1TXNRD3TXNRD2CYP1A2
SCHEMBL29180901 0.80 ALDH1A1 (0.49) ALDH1A1TXNRD1TXNRD3TXNRD2CYP1A2
SCHEMBL31399941 0.79 CYP1A2 (0.55) ALDH1A1TXNRD1TXNRD3TXNRD2CYP1A2
SCHEMBL1259501 0.79 CYP1A2 (0.55) ALDH1A1TXNRD1TXNRD3TXNRD2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118388419-A Preparation method of 2-chloro-7-nitroquinoxaline 武威广达科技有限公司 2024-07-26 — — CN claimed
US-12552804-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2026-02-17 — — US disclosed
EP-4583874-A1 MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) 2025-07-16 — — EP disclosed
US-20240287086-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2024-08-29 — — US disclosed
CN-118388419-A Preparation method of 2-chloro-7-nitroquinoxaline 武威广达科技有限公司 2024-07-26 — — CN disclosed
CN-118388419-A Preparation method of 2-chloro-7-nitroquinoxaline 武威广达科技有限公司 2024-07-26 — — CN disclosed
CN-118388419-A Preparation method of 2-chloro-7-nitroquinoxaline 武威广达科技有限公司 2024-07-26 — — CN disclosed
WO-2024132001-A1 MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) 2024-06-27 — — WO disclosed
CN-113896744-B Selective EGFR inhibitor 成都先导药物开发股份有限公司 2024-04-16 — — CN disclosed
CN-117586235-A Chimeric molecules for enhancing mitochondrial autophagy and uses thereof 广东省人民医院 2024-02-23 — — CN disclosed
US-8716280-B2 Bicyclic antibiotics BASILEA PHARMACEUTICA AG (CH) 2014-05-06 — — US disclosed
US-20130072457-A1 PYRAZOLYL QUINAZOLINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2013-03-21 — — US disclosed
US-20130072457-A1 PYRAZOLYL QUINAZOLINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2013-03-21 — — US disclosed
EP-2563775-A1 PYRAZOLYL QUINAZOLINE KINASE INHIBITORS Astex Therapeutics Limited (GB) 2013-03-06 — — EP disclosed
CN-102858765-A Pyrazolyl quinazoline kinase inhibitors ASTEX THERAPEUTICS LTD 2013-01-02 — — CN disclosed
CN-102361863-A Novel bicyclic antibiotics BASILEA PHARMACEUTICA AG 2012-02-22 — — CN disclosed
US-20120040957-A1 Novel Bicyclic Antibiotics BASILEA PHARMACEUTICA AG 2012-02-16 — — US disclosed
EP-2389376-A1 NOVEL BICYCLIC ANTIBIOTICS Basilea Pharmaceutica AG (CH) 2011-11-30 — — EP disclosed
WO-2011135376-A1 PYRAZOLYL QUINAZOLINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2011-11-03 — — WO disclosed
WO-2010084152-A1 NOVEL BICYCLIC ANTIBIOTICS BASILEA PHARMACEUTICA AG (CH) 2010-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072457-A1 PYRAZOLYL QUINAZOLINE KINASE INHIBITORS MAP3K5, MAP3K1, MAP4K2 ALDH1A1 3640/4885TXNRD1 1339/4885TXNRD3 1805/4885
US-20120040957-A1 Novel Bicyclic Antibiotics C5, C1S, CBR3 ALDH1A1 4235/4885TXNRD1 1262/4885TXNRD3 598/4885
US-20240287086-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR3, FGFR1, FGFR2 ALDH1A1 879/4885TXNRD1 2959/4885TXNRD3 4160/4885
US-12552804-B2 Tricyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 ALDH1A1 478/4885TXNRD1 2400/4885TXNRD3 2758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.